• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三阴性乳腺癌中γδ T细胞浸润的临床病理相关性

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer.

作者信息

Boissière-Michot Florence, Chabab Ghita, Mollevi Caroline, Guiu Séverine, Lopez-Crapez Evelyne, Ramos Jeanne, Bonnefoy Nathalie, Lafont Virginie, Jacot William

机构信息

Institut Régional du Cancer de Montpellier (ICM), Val d'Aurelle, 34298 Montpellier, France.

Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, 34298 Montpellier, France.

出版信息

Cancers (Basel). 2021 Feb 12;13(4):765. doi: 10.3390/cancers13040765.

DOI:10.3390/cancers13040765
PMID:33673133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7918092/
Abstract

The prognostic impact of the different tumor-infiltrating lymphocyte (TIL) subpopulations in solid cancers is still debated. Here, we investigated the clinicopathological correlates and prognostic impact of TILs, particularly of γδ T cells, in 162 patients with triple-negative breast cancer (TNBC). A high γδ T cell density (>6.625 γδ T cells/mm) was associated with younger age ( = 0.008), higher tumor histological grade ( = 0.002), adjuvant chemotherapy ( = 0.010), promoter methylation ( = 0.010), TIL density ( < 0.001), and PD-L1 ( < 0.001) and PD-1 expression ( = 0.040). In multivariate analyses, γδ T cell infiltration (cutoff = 6.625 γδ T cells/mm) was an independent prognostic factor (5-year relapse-free survival: 63.3% vs. 89.8%, = 0.027; 5-year overall survival: 73.8% vs. 89.9%, = 0.031, for low vs. high infiltration). This prognostic impact varied according to the tumor mutational status. High γδ T cell infiltration was associated with better survival in patients with wild-type tumors, but the difference was not significant in the subgroup with -mutated tumors. Altogether, these data suggest that high γδ T cell infiltrate is correlated with immune infiltration and might represent a candidate prognostic tool in patients with TNBC.

摘要

实体癌中不同肿瘤浸润淋巴细胞(TIL)亚群的预后影响仍存在争议。在此,我们研究了162例三阴性乳腺癌(TNBC)患者中TILs,尤其是γδT细胞的临床病理相关性及预后影响。高γδT细胞密度(>6.625个γδT细胞/mm)与较年轻的年龄(P = 0.008)、较高的肿瘤组织学分级(P = 0.002)、辅助化疗(P = 0.010)、启动子甲基化(P = 0.010)、TIL密度(P < 0.001)、PD-L1(P < 0.001)以及PD-1表达(P = 0.040)相关。在多变量分析中,γδT细胞浸润(临界值 = 6.625个γδT细胞/mm)是一个独立的预后因素(低浸润与高浸润的5年无复发生存率:63.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/727f1f8a12dc/cancers-13-00765-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/3e5877d44ef6/cancers-13-00765-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/e27185f7d632/cancers-13-00765-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/3a91f12f3ec8/cancers-13-00765-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/64d887e5e872/cancers-13-00765-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/6c9a56055cda/cancers-13-00765-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/727f1f8a12dc/cancers-13-00765-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/3e5877d44ef6/cancers-13-00765-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/e27185f7d632/cancers-13-00765-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/3a91f12f3ec8/cancers-13-00765-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/64d887e5e872/cancers-13-00765-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/6c9a56055cda/cancers-13-00765-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f68/7918092/727f1f8a12dc/cancers-13-00765-g006.jpg

相似文献

1
Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer.三阴性乳腺癌中γδ T细胞浸润的临床病理相关性
Cancers (Basel). 2021 Feb 12;13(4):765. doi: 10.3390/cancers13040765.
2
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌(TNBC)中肿瘤浸润淋巴细胞(TILs)和程序性死亡配体 1(PD-L1)表达的状态所阐明。
Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.
3
Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.肿瘤浸润淋巴细胞弥漫分布是三阴性乳腺癌预后较好和化疗效果较好的标志物。
Breast Cancer Res Treat. 2019 Nov;178(2):283-294. doi: 10.1007/s10549-019-05390-x. Epub 2019 Aug 12.
4
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.BRCA 基因突变不会影响三阴性乳腺癌中肿瘤浸润淋巴细胞的范围和组织。
Cancer Lett. 2019 May 28;450:88-97. doi: 10.1016/j.canlet.2019.02.027. Epub 2019 Feb 22.
5
Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.三阴性乳腺癌中与程序性死亡配体1表达相关的肿瘤浸润淋巴细胞的多光谱定量免疫组织化学分析
Breast Cancer. 2020 Jul;27(4):519-526. doi: 10.1007/s12282-020-01110-2. Epub 2020 May 23.
6
Infiltration of γ⁢δ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer.人乳腺癌中 γ⁢δ T 细胞、IL-17+T 细胞和 FoxP3+T 细胞的浸润。
Cancer Biomark. 2017 Dec 8;20(4):395-409. doi: 10.3233/CBM-170026.
7
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.三阴性乳腺癌新辅助化疗后残留肿瘤中肿瘤浸润性CD8 +和FOXP3 +淋巴细胞的预后意义及这些参数的变化:一项回顾性多中心研究
Breast Cancer Res. 2015 Sep 4;17(1):124. doi: 10.1186/s13058-015-0632-x.
8
Tumor infiltrating CD8 T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.在未经治疗的三阴性乳腺癌和肾细胞癌中,肿瘤浸润性CD8 T淋巴细胞计数与肿瘤TLR9状态无关。
Oncoimmunology. 2015 May 22;4(6):e1002726. doi: 10.1080/2162402X.2014.1002726. eCollection 2015 Jun.
9
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.在随机分配至辅助强化铂类化疗与常规化疗的 III 期乳腺癌患者中,肿瘤浸润淋巴细胞 (TILs) 和 BRCA 样状态。
Eur J Cancer. 2020 Mar;127:240-250. doi: 10.1016/j.ejca.2019.12.003. Epub 2020 Jan 16.
10
Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.启动子高甲基化与三阴性乳腺癌的良好预后和化疗敏感性相关。
Cancers (Basel). 2020 Mar 30;12(4):828. doi: 10.3390/cancers12040828.

引用本文的文献

1
Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer.整合多组学数据揭示了γδ T细胞在三阴性乳腺癌中的抗肿瘤作用及临床益处。
BMC Cancer. 2025 Apr 7;25(1):623. doi: 10.1186/s12885-025-14029-8.
2
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells.乳腺癌与肿瘤微环境:免疫细胞的关键作用
Curr Oncol. 2025 Feb 28;32(3):143. doi: 10.3390/curroncol32030143.
3
Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers.

本文引用的文献

1
Prognostic Value of CXCR2 in Breast Cancer.CXCR2在乳腺癌中的预后价值
Cancers (Basel). 2020 Jul 27;12(8):2076. doi: 10.3390/cancers12082076.
2
Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to γδ T Cell Cytotoxicity.异常表达的胚胎蛋白 NODAL 改变乳腺癌细胞对 γδ T 细胞细胞毒性的易感性。
Front Immunol. 2020 Jun 19;11:1287. doi: 10.3389/fimmu.2020.01287. eCollection 2020.
3
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Trop-2表达在非转移性三阴性乳腺癌中的预后价值及其与新兴生物标志物的相关性
Cancer Med. 2025 Mar;14(5):e70615. doi: 10.1002/cam4.70615.
4
The microenvironment cell index is a novel indicator for the prognosis and therapeutic regimen selection of cancers.微环境细胞指数是一种用于癌症预后和治疗方案选择的新型指标。
J Transl Med. 2025 Jan 13;23(1):61. doi: 10.1186/s12967-024-05950-w.
5
Blood immune profiling of Ethiopian patients with breast cancer highlights different forms of immune escape.埃塞俄比亚乳腺癌患者的血液免疫图谱揭示了不同形式的免疫逃逸。
Oncoimmunology. 2024 Dec 31;13(1):2436227. doi: 10.1080/2162402X.2024.2436227. Epub 2024 Dec 2.
6
The therapeutic role of γδT cells in TNBC.γδT 细胞在三阴性乳腺癌中的治疗作用。
Front Immunol. 2024 Jun 12;15:1420107. doi: 10.3389/fimmu.2024.1420107. eCollection 2024.
7
Gamma/delta T cells as cellular vehicles for anti-tumor immunity.γ/δ T细胞作为抗肿瘤免疫的细胞载体。
Front Immunol. 2024 Jan 11;14:1282758. doi: 10.3389/fimmu.2023.1282758. eCollection 2023.
8
A close look at current γδ T-cell immunotherapy.深入观察当前的 γδ T 细胞免疫疗法。
Front Immunol. 2023 Mar 31;14:1140623. doi: 10.3389/fimmu.2023.1140623. eCollection 2023.
9
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.TIGIT-PVR 免疫检查点轴与三阴性乳腺癌临床病理特征的相关性。
Front Immunol. 2022 Dec 5;13:1058424. doi: 10.3389/fimmu.2022.1058424. eCollection 2022.
10
Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer.CD206蛋白表达与三阴性乳腺癌患者免疫浸润及预后的相关性
Cancers (Basel). 2022 Oct 3;14(19):4829. doi: 10.3390/cancers14194829.
肿瘤浸润淋巴细胞、程序性细胞死亡配体-1、CD8 和 FOXP3 在三阴性乳腺癌预后模型中的整合:对 244 例接受标准治疗的 I-III 期患者的分析。
Eur J Cancer. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1.
4
Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers.实体瘤中肿瘤浸润 γδ T 细胞丰度的多样性。
Cells. 2020 Jun 24;9(6):1537. doi: 10.3390/cells9061537.
5
High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization.大剂量环磷酰胺给药可调控未成熟树突状细胞的表型和功能改变,并调节Th细胞极化。
Front Pharmacol. 2020 May 25;11:775. doi: 10.3389/fphar.2020.00775. eCollection 2020.
6
Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.鉴定人乳腺癌中表达 CD73 的调节性 Vδ1 γδ T 细胞亚群。
J Leukoc Biol. 2020 Jun;107(6):1057-1067. doi: 10.1002/JLB.3MA0420-278RR. Epub 2020 May 3.
7
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies.在确定预测免疫疗法反应的精确替代指标方面取得的进展。
Front Cell Dev Biol. 2020 Mar 17;8:155. doi: 10.3389/fcell.2020.00155. eCollection 2020.
8
Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.启动子高甲基化与三阴性乳腺癌的良好预后和化疗敏感性相关。
Cancers (Basel). 2020 Mar 30;12(4):828. doi: 10.3390/cancers12040828.
9
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.三阴性乳腺癌患者肿瘤浸润淋巴细胞的预后价值:系统评价和荟萃分析。
BMC Cancer. 2020 Mar 4;20(1):179. doi: 10.1186/s12885-020-6668-z.
10
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.